ADAM17 and metabolic dysfunction-associated steatohepatitis: Since RECK modulates the Notch pathway via direct inhibitory regulation of both ADAM10 and ADAM17, it is possible to speculate that RECK modulation could have a potential therapeutic function in NASH.